Approval for New Study Solid Tumors and Non-Hodgkin Lymphoma

Approval for New Study Solid Tumors and Non-Hodgkin Lymphoma

Antengene Corporation Limited today announced that China National Medical Products Administration (NMPA) has approved the Phase I study of ATG-101 (the PROBE-CN study) for the treatment of advanced/ metastatic solid tumors and B-cell non-Hodgkin lymphoma (B-NHL). ATG-101 is a novel bispecific antibody that was designed to block the binding of immunosuppressive PD-1/PD-L1 and conditionally induce 4-1BB stimulation, thus activating anti-tumor immune effectors, while delivering enhanced anti-tumor activity, with an improved safety profile. In preclinical studies, ATG-101 demonstrated significant anti-tumor activity […]

Click here to read: eTurboNews | TravelWireNews | TravelNewsOnline

Click here to read the full article.

Approval for New Study Solid Tumors and Non-Hodgkin Lymphoma

 

Source: eTurboNews

Related posts